Answers are grounded in this paper and cite their sources.
Tositumomab and iodine I-131 tositumomab (TST/I-131 TST; Bexxar), a radiolabeled anti-CD20 antibody, was approved in 2003 for the treatment of patients with rituximab-refractory, CD20-positive, fol...
No takes yet. Share an insight, caveat, or question.
Quackenbush et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: